Approach to diagnosis and management of reactivation of chronic hepatitis B

References

• Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4:545–558. doi:10.1016/S2468-1253(19)30119-0
   PubMed Web of Science ®Google Scholar
• Hepatitis B. 18 July 2018. Available from www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed June 20, 2019.
   Google Scholar
• Gentile G, Antonelli G. HBV reactivation in patients undergoing hematopoietic stem cell transplantation: a narrative review. Viruses 2019;11(11):1049. doi:10.3390/v11111049
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98. doi:10.1007/s12072-015-9675-4
   PubMed Web of Science ®Google Scholar
• Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200. doi:10.1136/bmj.m2200
   PubMedGoogle Scholar
• Mak LY, Seto WK, Fung J, Yuen MF. New biomarkers of chronic hepatitis B. Gut Liver. 2019;13:589–595. doi:10.5009/gnl18425
   PubMed Web of Science ®Google Scholar
• Doyle J, Raggatt M, Slavin M, et al. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Med J Aust. 2019;210(10):462–468. doi:10.5694/mja2.50160
   PubMed Web of Science ®Google Scholar
• Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–1309. doi:10.1053/j.gastro.2017.02.009
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–611. doi:10.1200/JCO.2008.18.0182
   PubMed Web of Science ®Google Scholar
• Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol. 1990;12(5):562–568. doi:10.1097/00004836-199010000-00015
   PubMed Web of Science ®Google Scholar
• Ekpanyapong S, Reddy KR. Hepatitis B virus reactivation: what is the issue, and how should it be managed? Clin Liver Dis. 2020;24:317–333. doi:10.1016/j.cld.2020.04.002
   PubMed Web of Science ®Google Scholar
• Wong GL, Yuen BW, Chan HL, et al. Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. Liver Int. 2019;39:271–279. doi:10.1111/liv.13953
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Arcaini L, Hong X, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133:137–146. doi:10.1182/blood-2018-04-848044
   PubMed Web of Science ®Google Scholar
• Pauly MP, Tucker LY, Szpakowski JL, et al. Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2018;16:1964–73 e1961. doi:10.1016/j.cgh.2018.04.033
   PubMed Web of Science ®Google Scholar
• De Pauli S, Grando M, Miotti G, Zeppieri M. Hepatitis B virus reactivation in patients treated with monoclonal antibodies. World J Virol. 2024;13(1):88487. doi:10.5501/wjv.v13.i1.88487
   PubMedGoogle Scholar
• Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15(5):1031–1048. doi:10.1007/s12072-021-10239-x
   PubMed Web of Science ®Google Scholar
• Wang Y, Han S-HB. Hepatitis B reactivation: a review of clinical guidelines. J Clin Gastroenterol. 2021;55(5):393–399. doi:10.1097/MCG.0000000000001520
   PubMed Web of Science ®Google Scholar
• Rammohan A. Current management & future directions in post-liver transplant recurrence of viral hepatitis. J Liver Transpl. 2021;3:2–5. doi:10.1016/j.liver.2021.100027
   Google Scholar
• Tonnini M, Solera Horna C, Ielasi L. Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies: Who and Why? World J Gastroenterol. 2024;30(5):509–511. doi:10.3748/wjg.v30.i5.509
   PubMed Web of Science ®Google Scholar
• Mak JWY, Law AWH, Law KWT, Ho R, Cheung CKM, Law MF. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World J Gastroenterol. 2023;29:4942–4961. doi:10.3748/wjg.v29.i33.4942
   PubMed Web of Science ®Google Scholar
• Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin Microbiol Infect. 2022;28:1321–1327. doi:10.1016/j.cmi.2022.02.042
   PubMed Web of Science ®Google Scholar
• Fu S, Zhang Q, Jing R, et al. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy. Bone Marrow Transplant. 2023;58;701–709. doi:10.1038/s41409-023-01960-2
   PubMed Web of Science ®Google Scholar
• Ding ZN, Meng GX, Xue JS, et al. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis. J Cancer Res Clin Oncol. 2023;149:1993–2008. doi:10.1007/s00432-022-04133-8
   PubMed Web of Science ®Google Scholar
• Su M, Ye T, Wu W, Shu Z, Xia Q. Possibility of PD-1/PD-L1 inhibitors for the treatment of patients with chronic hepatitis B infection. DigDis. 2023;42:3–4. doi:10.1159/000534535
   Google Scholar
• Doyle J, Raggatt M, Slavin M, et al. Hepatitis B management during immunosuppression for hematological and solid organ malignancies: an Australian consensus statement. Med J Aust. 2019;210(10):462–468. doi:10.5694/mja2.50160
   PubMed Web of Science ®Google Scholar